Sharp Fluidics has announced the acquisition of laparoscopic and robotic port site closure technology neoClose from neoSurgical for an undisclosed sum.

neoClose enables surgeons to close port site defects, up to 3cm, following laparoscopic and robotic abdominal surgery.

The technology uses bio-absorbable anchors with a pre-attached suture and is changing the standard of care in port site closure. It is considered to be quicker and safer and gives less port site pain compared to standard practices of closing port sites.

Sharp Fluidics president Doug Rimer said: “We strive to introduce innovative thinking to surgical closure, and neoClose is highly complementary to our Operative Armour System.

“With Operative Armour, clinicians can self-dispense and self-secure their own suture needles in open surgery closures without scrub tech assistance, dramatically improving workflow efficiency while minimising exposure to contaminated suture needles. neoClose enables us to now offer an extremely elegant and user-friendly, needleless approach to perform safer, more efficient closure of minimally invasive surgeries.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The acquisition of neoClose is expected to expand Sharp Fluidics’ product portfolio. The company’s Operative Armour System leads the way in open surgery closure efficiency and safety.

American Association of Hip and Knee Surgeons orthopaedic surgeon and former president Mark Froimson said: “neoClose and Operative Armour reduce OR surgical times and improve OR staff safety, two of the most important initiatives that many leading hospitals have prioritised.”

neoClose is neoSurgical’s initial product and is approved in the US and Europe for commercial sale.

Surgical device company Sharp Fluidics specialises in developing and marketing medical technologies and devices to enhance surgical closure efficiency and safety.